Galmed Pharmaceuticals Ltd. (GLMD) Q4 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the GALMED conference call to discuss financial results for the fourth quarter and year-end 2021. Today's conference is being recorded. Before we begin, please note that we will be making certain forward-looking statements on today's call, including those regarding financial results statements and forecasts regarding anticipated timelines and expectations with respect to our regulatory and clinical development programs. as well as other statements that relate to future events. These statements are based on the beliefs and expectations of management as of today, and actual results, trends, timelines, and projections relating to our financial position and projected development programs and pipeline could differ materially. We urge all investors to read carefully the risks and uncertainties disclosed in our filings with the SEC. Including without limitation, the risk under the heading risk factors described in our latest annual report on Form 20F filed with the SEC. Gallimant assumes no obligations to update any forward-looking statements or information, which speak as of their respective dates only. I would now like to turn the call over to Alan Bariff, President and Chief Executive Officer. Alan, please go ahead. Thank you, Peter. Good morning, and thank you for joining us on today's conference call. I'm pleased to be here today with our Chief Scientific Officer, Dr. Liat Hayardeni, our Chief Financial Officer, Daron Cohen, and Chief Accounting Officer, Yochai Stensler, to provide you with an update on our clinical development programs, as well as report to you on our financial results for the 2021 fourth quarter and full year financial results. As always, we will be happy to take any question you may have at the conclusion of our prepared rema...